Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.06 per share a year ago.
Entrada's quarterly revenue fell from $94.7M in 2024Q2 to $898.0K in 2026Q2 (down 53.9% year over year), while R&D of $35.4M and SG&A of $10.5M drive operating losses near $45.0M per quarter, suggesting the fundamental story now rests almost entirely on pipeline progress rather than commercial traction.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.94+6.9% vs -$1.01 | $905,000-60.6% vs $2M |
Q3 2026 Aug 5, 2026 | -$1.01+3.7% vs -$1.05 | $898,000-59.8% vs $2M |
Q2 2026 May 7, 2026 | -$0.95+10.4% vs -$1.06 | $875,000-70.0% vs $3M |
Q1 2026 Feb 26, 2026 | -$0.94+28.8% vs -$1.32 | $1M-82.5% vs $7M |
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.06 per share a year ago.
-- All ELEVATE-44-201 Cohort 1 participants have completed open-label dosing, with data expected to be received by year-end 2026 -- -- Company on track to report ELEVATE-44-201 Cohort 2 data in Q1 2027 – -- ELEVATE-45-201 Cohort 1 data reported in October 2026 met the primary objective of favorable safety and tolerability at an initial dose of 5 mg/kg -- -- ELEVATE-45-201 Cohort 2 enrollment complete and Company on track to report data in H1 2027 -- -- Expected cash runway extended into Q4 2027 with $193 million in cash, cash equivalents and marketable securities as of September 30, 2026 -- BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the third quarter ended September 30, 2026, and highlighted recent business updates. “The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.
Entrada Therapeutics (NASDAQ: TRDA - Get Free Report) and X4 Pharmaceuticals (NASDAQ: XFOR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability. Insider and Institutional Ownership 86.4% of Entrada
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer. “Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics.
Benchmark TRDA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Entrada Therapeutics, Inc. (TRDA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.03 | $195.27M | -1.32 | -87.94% | -4057.98% | -64% | — | |
| $43.11 | $6.07B | -8.43 | -45.65% | -160.64% | -172.62% | — | |
| $9.77 | $1.1B | -3.21 | 16.92% | -805.75% | -64.73% | — | |
| $21.01 | $2.16B | -20.54 | 120.01% | -73.04% | -9.69% | — | |
| $1.77 | $271.63M | -3.76 | 25.39% | -144.95% | -130.43% | — | |
| $40.19 | $3.88B | -8.52 | -89.97% | -1812.07% | -25.59% | — |
Entrada Therapeutics, Inc. (TRDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Entrada Therapeutics, Inc. (TRDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 10, 2026·SEC
May 19, 2026·SEC
Get notified when TRDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Entrada Therapeutics, Inc. (TRDA) stock FAQ — growth, dividends, profitability & financials explained
Entrada Therapeutics, Inc. (TRDA) reported $4.0M in revenue over the trailing twelve months. Revenue was $25.4M in fiscal year 2025.
Entrada Therapeutics, Inc. (TRDA) revenue fell by 93.5% over the trailing twelve months, compared with the twelve months before.
No. Entrada Therapeutics, Inc. (TRDA) reported a net loss of $161.4M over the trailing twelve months.
Entrada Therapeutics, Inc. (TRDA) had a return on equity (ROE) of -64.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Entrada Therapeutics, Inc. (TRDA) had negative free cash flow of $136.3M over the trailing twelve months.